Nothing Special   »   [go: up one dir, main page]

SG11201903287PA - Anti-respiratory syncytial virus antibodies, and methods of their generation and use - Google Patents

Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Info

Publication number
SG11201903287PA
SG11201903287PA SG11201903287PA SG11201903287PA SG11201903287PA SG 11201903287P A SG11201903287P A SG 11201903287PA SG 11201903287P A SG11201903287P A SG 11201903287PA SG 11201903287P A SG11201903287P A SG 11201903287PA SG 11201903287P A SG11201903287P A SG 11201903287PA
Authority
SG
Singapore
Prior art keywords
international
methods
rule
generation
pct
Prior art date
Application number
SG11201903287PA
Inventor
Laura M Walker
Original Assignee
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc filed Critical Adimab Llc
Publication of SG11201903287PA publication Critical patent/SG11201903287PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 April 2018 (26.04.2018) WIP0 I PCT olimion °nolo ovinciolu mom oimIE (10) International Publication Number WO 2018/075961 Al (51) International Patent Classification: A61K 39/12 (2006.01) C07K 16/10 (2006.01) (21) International Application Number: PCT/US2017/057720 (22) International Filing Date: 20 October 2017 (20.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/411,500 21 October 2016 (21.10.2016) US (71) Applicant: ADIMAB, LLC [US/US]; 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). (72) Inventor: WALKER, Laura M.; c/o Adimab, LLC, 7 Lu- cent Drive, Lebanon, New Hampshire 03766 (US). (74) Agent: SAHR, Robert N. et al.; Choate, Hall & Ste- wart LLP, Two International Place, Boston, Massachusetts 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) — Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) 1-1 1 - 1 N O CO (54) Title: ANTI-RESPIRATORY SYNCYTIAL VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE 0 (57) : Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as \" methods for their identification, isolation, generation, and methods for their preparation and use are provided.
SG11201903287PA 2016-10-21 2017-10-20 Anti-respiratory syncytial virus antibodies, and methods of their generation and use SG11201903287PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662411500P 2016-10-21 2016-10-21
PCT/US2017/057720 WO2018075961A1 (en) 2016-10-21 2017-10-20 Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Publications (1)

Publication Number Publication Date
SG11201903287PA true SG11201903287PA (en) 2019-05-30

Family

ID=60263074

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903287PA SG11201903287PA (en) 2016-10-21 2017-10-20 Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Country Status (12)

Country Link
US (2) US11312761B2 (en)
EP (1) EP3528840A1 (en)
JP (2) JP2020503844A (en)
KR (1) KR102695416B1 (en)
CN (1) CN110035771B (en)
AU (1) AU2017345759B2 (en)
BR (1) BR112019008063A2 (en)
CA (1) CA3040886A1 (en)
IL (3) IL293585B2 (en)
MX (1) MX2019004448A (en)
SG (1) SG11201903287PA (en)
WO (1) WO2018075961A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JP2020503843A (en) 2016-10-21 2020-02-06 アディマブ， エルエルシー Anti-respiratory syncytial virus antibodies and methods for their production and use
JP2020503844A (en) 2016-10-21 2020-02-06 アディマブ， エルエルシー Anti-respiratory syncytial virus antibodies and methods for their production and use
AR123405A1 (en) * 2018-12-21 2022-11-30 23Andme Inc ANTI-IL-36 ANTIBODIES AND METHODS OF USE THEREOF
WO2021138409A2 (en) * 2019-12-31 2021-07-08 Medstar Health, Inc. Anti-cd160 binding molecules for treating diseases
CN111172195A (en) * 2020-02-13 2020-05-19 翁炳焕 Preparation method of new coronary pneumonia gene therapy product
KR102467943B1 (en) 2020-06-25 2022-11-16 재단법인 목암생명과학연구소 Anti-RSV antibodies and pharmaceutical composition including the antibodies
CN112048006B (en) * 2020-09-08 2021-04-27 扬州大学 ELISA method for replacing neutralization efficacy determination and application thereof
EP4259654A1 (en) * 2020-12-08 2023-10-18 Humabs Biomed SA Antibodies binding to f-protein of metapneumovirus and uses thereof
CN114644708B (en) * 2020-12-18 2023-06-27 珠海泰诺麦博生物技术有限公司 Respiratory syncytial virus specific binding molecules
WO2022170126A2 (en) * 2021-02-05 2022-08-11 Adagio Therapeutics, Inc. Compounds specific to coronavirus s protein and uses thereof
CN118159556A (en) * 2021-08-25 2024-06-07 甘李药业股份有限公司 Anti-RSV virus antibodies and their applications
WO2024141063A1 (en) * 2022-12-30 2024-07-04 甘李药业股份有限公司 Anti-rsv antibody, composition and preparation, and use thereof
WO2024259075A1 (en) * 2023-06-14 2024-12-19 Tether Therapeutics, Inc. Polymer formulations for delivery of polynucleotides
WO2025015321A1 (en) * 2023-07-13 2025-01-16 Vir Biotechnology, Inc. Broadly neutralizing antibodies against rsv and mpv paramyxoviruses

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
JP3976333B2 (en) 1992-09-16 2007-09-19 ザ スクリップス リサーチ インスティチュート Human neutralizing monoclonal antibody against respiratory syncytial virus
NZ269735A (en) 1993-07-30 1998-01-26 Oravax Inc Monoclonal iga antibody against respiratory syncytial virus (rsv)
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
AU7240096A (en) 1995-09-18 1997-04-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Neutralizing monoclonal antibodies to respiratory syncytial virus
US20020141990A1 (en) 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
DK1223915T3 (en) 1999-10-29 2006-03-06 Nektar Therapeutics Dry powder preparations with improved dispersivity
DE60142614D1 (en) 2000-01-27 2010-09-02 Medimmune Inc INITÄT
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7700735B2 (en) 2000-03-01 2010-04-20 Medimmune, Llc High potency recombinant antibodies and method for producing them
WO2001064248A1 (en) 2000-03-02 2001-09-07 Medimmune, Inc. Methods of enhancing activity of vaccines and vaccine compositions
CA2407292A1 (en) 2000-05-03 2001-11-08 Medimmune, Inc. Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
ES2727425T3 (en) 2000-12-12 2019-10-16 Medimmune Llc Molecules with prolonged half-lives, compositions and uses thereof
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1613261A4 (en) 2003-04-09 2011-01-26 Novo Nordisk As INTRACELLULAR FORMATION OF PEPTIDE CONJUGATES
JP2007526208A (en) 2003-04-11 2007-09-13 メディミューン，インコーポレーテッド Methods for treating or preventing respiratory symptoms
US7070786B2 (en) 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7786273B2 (en) 2005-03-14 2010-08-31 Medimmune, Llc Macromolecules comprising a thioether cross-link
MX2009002174A (en) 2006-09-07 2009-03-12 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof.
DE102006060799A1 (en) * 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F protein and its use
KR20090127341A (en) 2007-03-06 2009-12-10 심포젠 에이/에스 Recombinant antibody for the treatment of respiratory syncytial virus infection
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
JP2011514139A (en) 2007-09-07 2011-05-06 シムフォゲン・アクティーゼルスカブ Method for recombinant production of anti-RSV antibodies
US7867497B2 (en) 2007-09-24 2011-01-11 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses therefor
KR100938998B1 (en) 2008-01-08 2010-01-28 (주) 에이프로젠 Antibodies to Respiratory Synstium Virus
JP5575377B2 (en) 2008-07-18 2014-08-20 シスメックス株式会社 RS virus detection kit and immunochromatography test device using anti-RS virus monoclonal antibody, and novel anti-RS virus monoclonal antibody
DK2387583T3 (en) 2009-01-14 2019-01-14 Ablynx Nv PULMONAL ADMINISTRATION OF VARIABLE IMMUNGLOBULIN SINGLE DOMAINS AND CONSTRUCTIONS THEREOF.
NZ597314A (en) 2009-06-05 2013-07-26 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
CA2770737C (en) * 2009-08-13 2020-05-12 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (rsv) and methods of use
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
CA2805547C (en) 2010-07-09 2020-01-07 Crucell Holland B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
CN105073196B (en) 2013-02-01 2020-04-07 米迪缪尼有限公司 Respiratory syncytial virus F protein epitope
TWI659968B (en) 2013-03-14 2019-05-21 再生元醫藥公司 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
AU2014231357B2 (en) * 2013-03-15 2018-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epitope of RSV fusion protein and antibody identifying same
EP2991679A4 (en) 2013-04-29 2016-12-07 Adimab Llc MULTISPECIFICITY REAGENTS, METHODS OF PREPARATION AND USE THEREOF
CN104293741A (en) * 2014-10-10 2015-01-21 武汉大学 Respiratory syncytial virus virus-like particle vaccine as well as preparation method and application thereof
CN107405397B (en) 2014-10-27 2020-08-25 新加坡科技研究局 Anti-TIM-3 antibody
US10713731B2 (en) 2016-07-22 2020-07-14 Nec Corporation Method for secure ledger distribution and computer system using secure distributed ledger technology
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JP2020503843A (en) 2016-10-21 2020-02-06 アディマブ， エルエルシー Anti-respiratory syncytial virus antibodies and methods for their production and use
JP2020503844A (en) 2016-10-21 2020-02-06 アディマブ， エルエルシー Anti-respiratory syncytial virus antibodies and methods for their production and use

Also Published As

Publication number Publication date
CN110035771B (en) 2024-03-08
AU2017345759A1 (en) 2019-05-23
US20220144922A1 (en) 2022-05-12
WO2018075961A1 (en) 2018-04-26
BR112019008063A2 (en) 2019-07-02
KR102695416B1 (en) 2024-08-13
IL293585B2 (en) 2023-11-01
RU2019115249A3 (en) 2021-02-01
JP2020503844A (en) 2020-02-06
JP7524155B2 (en) 2024-07-29
NZ753071A (en) 2024-04-26
EP3528840A1 (en) 2019-08-28
JP2022028898A (en) 2022-02-16
MX2019004448A (en) 2019-08-14
US12116401B2 (en) 2024-10-15
AU2017345759B2 (en) 2024-06-20
US20190256581A1 (en) 2019-08-22
CA3040886A1 (en) 2018-04-26
KR20190103147A (en) 2019-09-04
CN110035771A (en) 2019-07-19
US11312761B2 (en) 2022-04-26
RU2019115249A (en) 2020-11-24
IL303833A (en) 2023-08-01
IL293585B1 (en) 2023-07-01
IL266101A (en) 2019-06-30
IL293585A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201807912SA (en) Vaccine against rsv
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201909949XA (en) Targeted immunotolerance
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201906163TA (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201901351UA (en) A patient interface, system and method
SG11201901457TA (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201805001UA (en) Method of treating influenza a